These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22743083)

  • 1. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
    Nishino M; Cryer SK; Okajima Y; Sholl LM; Hatabu H; Rabin MS; Jackman DM; Johnson BE
    Cancer Imaging; 2012 Jun; 12(1):225-35. PubMed ID: 22743083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.
    Marom EM; Martinez CH; Truong MT; Lei X; Sabloff BS; Munden RF; Gladish GW; Herbst RS; Morice RC; Stewart DJ; Jimenez CA; Blumenschein GR; Onn A
    J Thorac Oncol; 2008 Apr; 3(4):351-7. PubMed ID: 18379352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.
    Yip C; Tacelli N; Remy-Jardin M; Scherpereel A; Cortot A; Lafitte JJ; Wallyn F; Remy J; Bassett P; Siddique M; Cook GJ; Landau DB; Goh V
    J Thorac Imaging; 2015 Sep; 30(5):300-7. PubMed ID: 26164165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
    Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
    Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy].
    Huang C; Wang LC; Xiao JY; Ye ZX; Liu ZJ; Xu WJ; Cheng X; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):712-5. PubMed ID: 19173919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
    Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
    J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
    Crabb SJ; Patsios D; Sauerbrei E; Ellis PM; Arnold A; Goss G; Leighl NB; Shepherd FA; Powers J; Seymour L; Laurie SA
    J Clin Oncol; 2009 Jan; 27(3):404-10. PubMed ID: 19047292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
    Kim YN; Lee HY; Lee KS; Seo JB; Chung MJ; Ahn MJ; Park K; Kim TS; Yi CA
    Korean J Radiol; 2012; 13(6):702-10. PubMed ID: 23118568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.
    De Braganca KC; Janjigian YY; Azzoli CG; Kris MG; Pietanza MC; Nolan CP; Omuro AM; Holodny AI; Lassman AB
    J Neurooncol; 2010 Dec; 100(3):443-7. PubMed ID: 20440540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
    JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
    Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
    Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
    Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ
    Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
    Reck M; Barlesi F; Crinò L; Henschke CI; Isla D; Stiebeler S; Spigel DR
    Ann Oncol; 2012 May; 23(5):1111-1120. PubMed ID: 22056855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment.
    Huang Y; Yang Y; Qu A; Li S; Chen D; Zou H; Li S; Zhang Y; Zhuang W; Su J; Zhou X; Zhang Y
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):101-108. PubMed ID: 37898825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
    Schmid-Bindert G
    Target Oncol; 2013 Mar; 8(1):15-26. PubMed ID: 23371029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.